CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER 074107

CHEMISTRY REVIEW(S)

1/N

1. CHEMIST'S REVIEW NO. 5

2. ANDA # 74-107

3. NAME AND ADDRESS OF APPLICANT

Sidmak Laboratories, Inc.
17 West Street
P.O. Box 371
East Hanover, NJ 07936

4. LEGAL BASIS FOR ANDA SUBMISSION

Tenoretic Tablets- ICI Pharma

5. SUPPLEMENT(s): N/A

6. PROPRIETARY NAME

7. NONPROPRIETARY NAME

Atenolol and Chlorthalidone

8. SUPPLEMENT(s) PROVIDE(s) FOR: N/A

9. AMENDMENTS AND OTHER DATES:

Firm:

8-21-91: Original submission
5-31-95: Amendment
9-25-96: Amendment
5-5-97: Amendment
7-7-97: Telephone amendment
8-27-97: Telephone amendment

FDA:

10-7-91: Acknowledgement
9-18-91: EER request(not sent)
2-11-92: 1st NA letter
2-12-96: 2nd NA letter
4-7-97: 3rd NA letter
6-23-97: 4th NA letter from telephone
7-11-97: 5th NA letter from telephone

10. PHARMACOLOGICAL CATEGORY

11. Rx or OTC

antihypertensive agent

Rx

12. RELATED IND/NDA/DMF(s)

(b)4 - Confidential Business

13. DOSAGE FORM

Tablet

14. POTENCY

50 mg/25 mg (unscored) and 100 mg/25 mg (unscored)

15. CHEMICAL NAME AND STRUCTURE

Atenolol:



Molecular Formula: $C_{14}H_{22}N_2O_3$

Molecular Weight: 266.34

1. Benzeneacetamide, 4-(2-hydroxy-3-[(1-methylethyl) amino]-propoxyl]-;

2. 2-[p-[2-Hydroxy-3-(isopropylamino)propoxy] phenyl] acetamide.

A white or almost white powder, odorless or almost odorless. Sparingly soluble in water, soluble in absolute ethanol, practically insoluble in ether. Melting point 152 - 155°C.

Chlorthalidone:



Molecular Formula: $C_{14}H_{11}ClN_2O_4S$

Molecular Weight: 338.76

1. Benzene-sulfonamide, 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-yl)-;

2. 2-Chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)

benzenesulfonamide.

A white or creamy-white, crystalline powder, odorless or almost odorless. Practically insoluble in water (12 mg/100 mL at 20°C, 27 mg/100 mL at 37°C), slightly soluble in ethanol (96%), soluble in 25 parts methanol. It dissolves in solutions of alkali hydroxides. Melting point about 220°C with decomposition.

16. RECORDS AND REPORTS: N/A

17. COMMENTS

Q: Please submit the revised release specification of the finished product per USP 23 requirements to include TLC for Identification testing A.

A: OK (see 7-7-97 amendment).

Status:

a. EER status: **Satisfactory**

(b)4 - Confidential Business

(Withdrawn) by Lucia Tang on 9-28-95 and acceptable on 12-23-95. Pre-approval and updated EER was requested by L Tang on 3-6-97 and **found acceptable on 7-9-97.**

b. Method Validation status: **Satisfactory**

Two copies of analytical methodology for both the active ingredient and the finished dosage form for the method validation package were sent to Philadelphia District Office on 12-28-95 and found satisfactory on 8-12-96. The drug substance and the drug product are now articles in USP 23, supplement 4.

c. Bio-review: **Satisfactory** for old batches, **Satisfactory** for new batch lot 94-018T with minor modification to the process and formulation.

Satisfactory per J. Henderson reviewed on 5-20-93. OK from Lizzie Sanchez's E-Mail on June 3, 1997 and acceptable by M. Kochhar on 6-24-97.

100 mg/25 mg Tablets and 50 mg/25 mg Tablets, Lots# 90-026-T and 91-024T.

d. Labeling review status: **satisfactory**

Satisfactory per J White reviewed on 12/10/96.

e. (b)4 - Confidential Business

18. CONCLUSIONS AND RECOMMENDATIONS

This application is considered as APPROVAL.

19. REVIEWER: DATE COMPLETED:

Lucia C. Tang 9-2-97